Centerpoint Advisors’s Biogen BIIB Stock Holding History

Centerpoint Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18K	Hold	83	–	–	0.01%	281
2026 Q1	$15K	Hold	83	–	–	﹤0.01%	282
2025 Q4	$15K	Hold	83	–	–	﹤0.01%	291
2025 Q3	$12K	Hold	83	–	–	﹤0.01%	314
2025 Q2	$10K	Hold	83	–	–	﹤0.01%	309
2025 Q1	$11K	Hold	83	–	–	﹤0.01%	314
2024 Q4	$13K	Sell	83 -84	-50%	-$14.2K	﹤0.01%	326
2024 Q3	$32K	Hold	167	–	–	0.01%	213
2024 Q2	$39K	Hold	167	–	–	0.01%	198
2024 Q1	$36K	Hold	167	–	–	0.01%	192
2023 Q4	$43K	Hold	167	–	–	0.02%	165
2023 Q3	$43K	Hold	167	–	–	0.02%	158
2023 Q2	$48K	Hold	167	–	–	0.02%	163
2023 Q1	$46K	Hold	167	–	–	0.02%	164
2022 Q4	$46K	Hold	167	–	–	0.02%	146
2022 Q3	$45K	Hold	167	–	–	0.02%	134
2022 Q2	$34K	Hold	167	–	–	0.02%	161
2022 Q1	$35K	Hold	167	–	–	0.02%	167
2021 Q4	$40K	Buy	+167	New	+$42.9K	0.02%	146
2018 Q2	–	Sell	-1	Closed	–	–	370
2018 Q1	$0	Buy	+1	New	+$310	﹤0.01%	246

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centerpoint Advisors's BIIB Position: Q2 2026 in Review

Centerpoint Advisors held its Biogen (BIIB) position steady in Q2 2026 at 83 shares worth $18K. The position accounts for 0.01% of the portfolio, ranked #281.

Centerpoint Advisors first reported a position in BIIB in Q1 2018 and has held it in 20 quarters since. The position peaked at $48K in Q2 2023. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Centerpoint Advisors held 83 shares of Biogen worth $18K as of Q2 2026.
Centerpoint Advisors left its Biogen share count unchanged in Q2 2026.
Biogen made up 0.01% of Centerpoint Advisors's portfolio in Q2 2026, its #281 holding.
Centerpoint Advisors first reported a position in Biogen in Q1 2018 and has held it in 20 quarters since.
Centerpoint Advisors's Biogen position peaked at $48K in Q2 2023.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Centerpoint Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.